oncology-cancer-therapy-2019-posters-abstracts

Page 51

allied

academies

Journal of Medical Oncology & Therapeutics | Volume 4

March 18-19, 2019 | London, UK

Oncology & Cancer Therapy

International Conference on

Notes:

Tumor infiltrating lymphocytes and tertiary lymphoid structure as prognostic and predictive factor for

neoadjuvant chemotherapy in stage ii & iii breast cancer

Mohamed L

Tanta University, Egypt

Introduction

: Tumor-infiltrating lymphocytes (TILs) have a

strong prognostic and predictive value in triple-negative breast

cancer (TNBC) and HER2 enriched subtype but no other breast

subtypes but no studies have evaluated tertiary lymphoid

structure (TLS).

Materials and Methods

: Eighty patients with stage II and III

breast cancer in Tanta oncology and pathology departments

with luminal A, B and her 2 enriched and TNBC diagnosed with

core needle biopsy treated with neoadjuvant chemotherapy (4

AC followedby 12-week paclitaxel + herceptin). TIL and TLSwere

evaluated histopathologically using hematoxylin and eosin–

stained slides. The immune cell aggregates which were TLS

positive showed the presence of CD20+B lymphocytes within

the follicles, with areas of CD3+, CD4+ T lymphocytes mainly

in the periphery [T-cell zone] resembling the highly organized

structures of secondary lymphoid organs.

Results

: TLS were detected in 53.7% of the tumors in whole

breast groups, 83.7% in triple negative subgroup. Increased

number of tumor infiltrating lymphocytes and tertiary lymphoid

structure are associated with longer OS and DFS for TNBC and

HER2-positive breast cancer.